NOW AVAILABLE:

ZURZUVAE®
(zuranolone) CIV, for
the treatment of women
with postpartum
depression

U.S. Prescribing Information

U.S. Medication Guide

LEARN MORE

Seeing the brain differently
makes a world of difference

Learn More About Our Approach

PATIENTS & CARE PARTNERS Putting patients and their families first

We are rethinking care and how it is delivered to help patients and families impacted by brain health disorders.

See our resources for patients

Asian woman on a solid blue background wearing a gray t-shirt and a ponytail looking off into the distance

News The latest from Sage

See All News

Pipeline

Compound

Target Indications

Phase 1

Phase 2

Phase 3

Status

Postpartum Depression Commercial Products

ZURZUVAE^®^*
(zuranolone) CIV

Postpartum Depression

Marketed

ZULRESSO^®^**
(brexanolone) CIV injection

Postpartum Depression

Marketed

Pipeline

Dalzanemdor
(SAGE-718)

Huntington’s Disease Cognitive Impairment

IN PHASE 2

Programs In Evaluation

SAGE-324^***

GABA Hypofunction
SAGE-689

Acute GABA Hypofunction
SAGE-421

NMDA Hypofunction
SAGE-319

GABA Hypofunction

^*Collaboration Partners: Biogen Inc. and Shionogi for zuranolone
^**Sage plans to discontinue commercial availability of ZULRESSO in the U.S. as of December 31, 2024.
^***In July 2024, we announced discontinuation of clinical development of SAGE-324 in ET. Sage is evaluating next steps, if any, for other potential indications.

Please refer to the U.S. Prescribing Information for ZULRESSO and the U.S. Prescribing Information for ZURZUVAE
Safety and efficacy for investigational uses or compounds have not been established. There is no guarantee that the outcome of these studies will be positive or result in approval by a health authority.

LEARN MORE ABOUT OUR PROGRAMS AND RESEARCH

News The latest from Sage

press releases & statements

events & presentations

Sage Medical Hub

Pipeline